Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 2/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.54 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.54 |
| ▸ | S100A4 | P26447 | 2/20 | 0.49 |
| ▸ | LTK | P29376 | 1/20 | 0.47 |
| ▸ | MST1R | Q04912 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31316525 | 1.00 | CDK5 (0.54) | CDK5DYRK1ACLK4PIM1CSNK1A1 | |
| SCHEMBL16131526 | 0.89 | CDK5 (0.50) | CDK5DYRK1ACLK4PIM1CSNK1A1 | |
| SCHEMBL7581608 | 0.83 | PARP1 (0.57) | S100A4MAPTRECQLKMT2AMCL1 | |
| SCHEMBL16131489 | 0.82 | CDK5 (0.44) | CDK5DYRK1ACLK4PIM1CSNK1A1 | |
| SCHEMBL27426997 | 0.81 | S100A4 (0.43) | S100A4MAPTRECQLKMT2AMCL1 | |
| SCHEMBL2062086 | 0.75 | S100A4 (0.47) | S100A4MAPTRECQLKMT2AMCL1 | |
| SCHEMBL28936204 | 0.74 | CHEK1 (0.42) | CDK5DYRK1ACLK4PIM1CSNK1A1 | |
| SCHEMBL29919756 | 0.74 | CHEK1 (0.42) | CDK5DYRK1ACLK4PIM1CSNK1A1 | |
| SCHEMBL8873079 | 0.73 | TDP1 (0.40) | S100A4MAPTRECQLKMT2AMCL1 | |
| SCHEMBL29222583 | 0.73 | S100A4 (0.44) | CDK5DYRK1ACLK4PIM1CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| CN-114989141-B | Lenalidomide derivative and preparation method and application thereof | 济南爱思医药科技有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-114989141-A | Lenalidomide derivative and preparation method and application thereof | 济南爱思医药科技有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-103601717-A | Novel preparation method of lenalidomide | Hunan huateng pharmaceutical co ltd | 2014-02-26 | — | — | CN | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-119874700-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-04-25 | — | — | CN | disclosed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-12215105-B2 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| CN-114945366-B | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-114773424-B | A bioactive androstanol derivative, and its preparation method and application | 济南爱思医药科技有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030149050-A1 | Inhibitors of inflammation and reperfusion injury and methods of use thereof | INOTEK CORP. | 2003-08-07 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-6534651-B2 | Substituted isoindolinone derivatives | INOTEK PHARMACEUTICALS CORP. | 2003-03-18 | — | — | US | disclosed |
| US-6534651-B2 | Substituted isoindolinone derivatives | INOTEK PHARMACEUTICALS CORP. | 2003-03-18 | — | — | US | disclosed |
| US-6534651-B2 | Substituted isoindolinone derivatives | INOTEK PHARMACEUTICALS CORP. | 2003-03-18 | — | — | US | disclosed |
| US-20020095044-A1 | Inhibitors of inflammation and reperfusion injury and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2002-07-18 | — | — | US | disclosed |
| WO-2001077075-A2 | INHIBITORS OF INFLAMMATION AND REPERFUSION INJURY | INOTEK CORPORATION (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020095044-A1 | Inhibitors of inflammation and reperfusion injury and methods of use thereof | IL1B, PTGS1, MMP8 | CDK5 411/4885DYRK1A 3592/4885CLK4 2132/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | CDK5 777/4885DYRK1A 2470/4885CLK4 4298/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | CDK5 934/4885DYRK1A 860/4885CLK4 198/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | CDK5 1211/4885DYRK1A 4802/4885CLK4 3903/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | CDK5 504/4885DYRK1A 2254/4885CLK4 3435/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CDK5 1211/4885DYRK1A 4802/4885CLK4 3903/4885 |
| US-20030149050-A1 | Inhibitors of inflammation and reperfusion injury and methods of use thereof | IL1B, PTGS1, MMP8 | CDK5 411/4885DYRK1A 3592/4885CLK4 2132/4885 |
| US-12215105-B2 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | CDK5 934/4885DYRK1A 860/4885CLK4 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.